🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

14+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 14 of 14 recruiting trials for “Thalassemia”

Phase 2RecruitingNCT07338344 ↗

Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients

🏥 Rongrong Liu📍 8 sites📅 Started Feb 2026View details ↗
NARecruitingNCT07112703 ↗

Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia Major

🏥 Rawan Mohammed Khairy Mostafa Elsawy📍 1 site📅 Started Apr 2025View details ↗
Phase 3RecruitingNCT06609226 ↗

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

👨‍⚕️ Clinical Transparency (dept. 2834), Novo Nordisk A/S📍 103 sites📅 Started Jan 2025View details ↗
NARecruitingNCT06931912 ↗

Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Dec 2024View details ↗
Phase 2RecruitingNCT06657391 ↗

Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

🏥 Rongrong Liu📍 5 sites📅 Started Oct 2024View details ↗
Enrolling by InvitationNCT07003269 ↗

Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT

👨‍⚕️ Xiaoyang Yang, MD, Department of Hematology, Haikou People's Hospital📍 1 site📅 Started Sep 2024View details ↗
Phase 1RecruitingNCT06655662 ↗

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

👨‍⚕️ Chao Liu, PHD, Shenzhen Hemogen📍 3 sites📅 Started Jun 2024View details ↗
Phase 2RecruitingNCT06302491 ↗

A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

👨‍⚕️ Yusha Zhu, MD, PhD, Kind Pharmaceuticals LLC📍 5 sites📅 Started May 2024View details ↗
NARecruitingNCT06041620 ↗

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

👨‍⚕️ Jun Shi, PhD, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Aug 2023View details ↗
NARecruitingNCT05776173 ↗

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

👨‍⚕️ Sujiang Zhang, M.D., Ruijin Hospital, Shanghai, China📍 1 site📅 Started Aug 2023View details ↗
Phase 1RecruitingNCT05757245 ↗

A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants

🏥 First Affiliated Hospital of Guangxi Medical University📍 1 site📅 Started May 2023View details ↗
RecruitingNCT06314529 ↗

Long-term Follow-up Study of BHC001 for TDT

👨‍⚕️ Xiaochen Wang, PhD, Bioray Laboratories📍 2 sites📅 Started Dec 2022View details ↗
EARLY_Phase 1RecruitingNCT05851105 ↗

the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

👨‍⚕️ Chao Liu, PHD, Shenzhen Hemogen📍 1 site📅 Started Oct 2022View details ↗
EARLY_Phase 1RecruitingNCT05864170 ↗

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

👨‍⚕️ Chao Liu, PHD, Shenzhen Hemogen📍 1 site📅 Started May 2022View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →